专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP2183278B1 NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY 失效
公开(公告)号：EP2183278B1
公开(公告)日：2018-07-04
申请号：EP08785106.9
申请日：2008-07-25
申请人： Immatics Biotechnologies GmbH
发明人： SINGH, Harpreet , SCHOOR, Oliver , TRAUTWEIN, Claudia , HILF, Norbert , WEINSCHENK, Toni , WALTER, Steffen , LEWANDROWSKI, Peter
IPC分类号： C07K14/47 , A61K39/00
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
摘要： The present invention relates to amino acid sequences of peptides derived from tumour associated antigens that are able to bind to MHC complexes of either class, and elicit an immune response, as well as to uses of said peptides for the treatment of diseases.

2. 发明公开

EP3292869A1 KAL1 PROTEIN CONTROLLING CELL CYCLE OF HEMATOPOIETIC STEM CELL, AND USE THEREOF 有权
标题翻译： KAL1蛋白控制造血干细胞的细胞周期及其应用
公开(公告)号：EP3292869A1
公开(公告)日：2018-03-14
申请号：EP16789620.8
申请日：2016-05-04
申请人： Seoul National University R & DB Foundation
发明人： KIM, Hyo-Soo , HUR, Jin , CHOI, Jae Il
IPC分类号： A61K38/17 , C12N5/0789 , C07K14/705 , A61K35/28
CPC分类号： A61K35/28 , A61K38/17 , A61K2035/124 , A61P35/00 , C07K14/705 , C12N5/0081 , C12N5/0634 , C12N2502/1157 , C12N2502/1171
摘要： The present invention relates to a KAl1 protein controlling the cell cycle of a hematopoietic stem cell and a use thereof, and more specifically, a composition comprising a KAl1(CD82) polypeptide or a gene encoding the same for controlling the cell cycle of a hematopoietic stem cell, or a pharmaceutical composition for preventing or treating blood tumors. In the present invention, KAI1(CD82) is expressed only in a hematopoietic stem cell (LT-HSC) which is the uppermost stem cell in the hierarchy of the hematopoietic stem cell, can obtain an LT-HSC with high purity using the KAl1, and thus can inhibit various side effects of hematopoietic stem cell transplantation by transplanting only an LT-HSC with high purity. In addition, KAl1 importantly acts on the quiescence of an LT-HSC, and has resistance against cell damage due to various stresses (5-FU, irradiation, etc.) by maintaining the quiescence of the LT-HSC. Thus, it is expected that the cell can be used for making a cell bank and can be used as a blood tumor cell therapy product through cell transplantation.
摘要翻译：本发明涉及控制造血干细胞的细胞周期的KAl1蛋白及其用途，更具体地涉及包含KAl1（CD82）多肽或编码其的用于控制造血干细胞的细胞周期的基因的组合物细胞或用于预防或治疗血液肿瘤的药物组合物。在本发明中，KAI1（CD82）仅在造血干细胞层次中最上层的干细胞 - 造血干细胞（LT-HSC）中表达，可以使用KAl1获得高纯度的LT-HSC，因此通过仅移植高纯度的LT-HSC可以抑制造血干细胞移植的各种副作用。此外，KAl1通过维持LT-HSC的静止而重要地作用于LT-HSC的静止，并且具有抗各种应激（5-FU，辐射等）引起的细胞损伤。因此，预计细胞可用于制造细胞库，并可通过细胞移植用作血液肿瘤细胞治疗产品。

3. 发明公开

EP2941256A1 CD11b- low MACROPHAGES AND CONDITIONED MEDIA THEREOF FOR TREATING CANCER AND/OR FIBROSIS 有权
标题翻译：巨噬细胞低CD11b的内容和条件培养基及其用于癌症和/或纤维化的治疗
公开(公告)号：EP2941256A1
公开(公告)日：2015-11-11
申请号：EP13867603.6
申请日：2013-12-30
申请人： Carmel-Haifa University Economic Corporation Ltd
发明人： BARKAN, Dalit , GILON, Odelya , ARIEL, Amiram , SCHIF-ZUCK, Sagie
IPC分类号： A61K35/12 , C12N5/0786
CPC分类号： A61K35/15 , A61K35/12 , A61K45/06 , C12N5/0645 , C12N5/0656 , C12N2500/70 , C12N2501/15 , C12N2501/58 , C12N2502/00 , C12N2502/1157 , C12N2506/11 , C12N2506/115 , C12N2506/1307
摘要： A conditioned medium of CD11blow macrophages and methods for preparing it are provided. Pharmaceutical compositions comprising the CD11blow macrophages conditioned medium or a culture of CD11blow macrophages and their use in the treatment of cancer or fibrosis are also provided.

4. 发明公开

EP2562184A1 Novel immunogenic epitopes for immunotherapy 失效转让
公开(公告)号：EP2562184A1
公开(公告)日：2013-02-27
申请号：EP12191628.2
申请日：2008-07-25
申请人： Immatics Biotechnologies GmbH
发明人： Singh, Harpreet , Schoor, Oliver , Trautwein, Claudia , Hilf, Norbert , Weinschenk, Toni , Walter, Steffen , Lewandrowski, Peter
IPC分类号： C07K14/47 , A61K39/00 , C07K14/495
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
摘要： The present invention relates to amino acid sequences of peptides derived from tumour associated antigens that are able to bind to MHC complexes of either class, and elicit an immune response, as well as to uses of said peptides for the treatment of diseases.

5. 发明公开

EP2562183A1 Novel immunogenic epitopes for immunotherapy 失效
公开(公告)号：EP2562183A1
公开(公告)日：2013-02-27
申请号：EP12191623.3
申请日：2008-07-25
申请人： Immatics Biotechnologies GmbH
发明人： Singh, Harpreet , Schoor, Oliver , Trautwein, Claudia , Hilf, Norbert , Weinschenk, Toni , Waltere, Steffen , Lewandrowski, Peter
IPC分类号： C07K14/47 , A61K39/00 , C12N9/90
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
摘要： The present invention relates to amino acid sequences of peptides derived from tumour associated antigens that are able to bind to MHC complexes of either class, and elicit an immune response, as well as to uses of said peptides for the treatment of diseases.

6. 发明公开

EP2193805A1 IMMUNOSUPPRESSION WEANING AGENT COMPRISING TUMOR CELL AND ANTITUMOR AGENT USING THE SAME 审中-公开
标题翻译：免疫抑制剂 - 美国麻省理工学院麻省理工学院
公开(公告)号：EP2193805A1
公开(公告)日：2010-06-09
申请号：EP08792646.5
申请日：2008-08-22
申请人： Keio University
发明人： KUDO, Chie , KAWAKAMI, Yutaka
IPC分类号： A61K45/00 , A61K35/12 , A61K38/00 , A61K39/395 , A61K48/00 , A61P35/00 , A61P35/04 , A61P37/02 , A61P37/04 , A61P37/06 , A61P37/08 , A61P43/00
CPC分类号： C07K16/2866 , A61K31/00 , A61K38/1709 , A61K38/1793 , A61K38/195 , A61K2039/505 , C07K14/4702 , C07K16/18 , C07K16/24 , C07K16/30 , C07K2317/73 , C12N5/0693 , C12N15/113 , C12N2310/14 , C12N2501/148 , C12N2502/1114 , C12N2502/1157 , C12N2502/30 , C12N2510/00
摘要： In order to provide a gene expression enhancer for enhancing expression of FoxP3 gene in a cell; a cell differentiation inducer for inducing differentiation of a cell into a regulatory T cell; an immunosuppressor for suppressing immunity and an agent for treating hyperimmune diseases based on the abovementioned actions; an inhibitor of enhancement of gene expression for inhibiting enhancement of expression of FoxP3 gene in a cell; an inhibitor of induction of cell differentiation for inhibiting induction of differentiation of a cell into a regulatory T cell; a reducer of immunosuppression for reducing immunosuppression, a stimulator of tumor immunity and an antitumor agent based on the abovementioned actions; and the like, for example, an agent containing at least one of a cell expressing Snail protein, MCP1 protein, FSTL1 protein, membrane IL-13Ra2 protein or secretory IL-13Ra2 protein, or MCP1 protein, FSTL1 protein or secretory IL-13Ra2 protein, is used as a gene expression enhancer for FoxP3, an inducer of regulatory T cell differentiation, an immunosuppressor or an agent for treating hyperimmune diseases; and an agent containing an anti-MCP1 antibody, an anti-FSTL1 antibody or an anti-IL-13Ra2 antibody is used as an inhibitor of enhancement of FoxP3 gene expression, a reducer of immunosuppression, a stimulator of tumor immunity, an antitumor agent, or the like.
摘要翻译：为了提供用于增强细胞中FoxP3基因表达的基因表达增强子; 用于诱导细胞分化成调节性T细胞的细胞分化诱导物; 用于抑制免疫的免疫抑制剂和基于上述作用的用于治疗超免疫疾病的药剂; 用于抑制细胞中FoxP3基因表达增强的基因表达增强抑制剂; 用于抑制诱导细胞分化成调节性T细胞的细胞分化诱导抑制剂; 用于减少免疫抑制的免疫抑制剂，肿瘤免疫的刺激剂和基于上述作用的抗肿瘤剂; 例如含有表达Snail蛋白，MCP1蛋白，FSTL1蛋白，膜IL-13Ra2蛋白或分泌型IL-13Ra2蛋白的细胞或MCP1蛋白，FSTL1蛋白或分泌型IL-13Ra2蛋白中的至少一种的药剂用作FoxP3基因表达增强子，FoxP3是调节性T细胞分化的诱导剂，免疫抑制剂或治疗超免疫疾病的药剂; 使用含有抗MCP1抗体，抗FSTL1抗体或抗IL-13Ra2抗体的药物作为FoxP3基因表达增强抑制剂，免疫抑制剂的减少剂，肿瘤免疫刺激剂，抗肿瘤剂，或类似物。

7. 发明公开

EP3368051A1 GENERATING HPV ANTIGEN-SPECIFIC T CELLS FROM A NAIVE T CELL POPULATION 审中-公开
公开(公告)号：EP3368051A1
公开(公告)日：2018-09-05
申请号：EP16861028.5
申请日：2016-10-31
申请人： Children's National Medical Center
发明人： BOLLARD, Catherine, M. , CRUZ, Conrad , HANLEY, Patrick, J.
IPC分类号： A61K35/12 , A61P37/04 , C12N5/0783 , C12N5/0784
CPC分类号： C12N5/0636 , A61K35/17 , A61P15/00 , A61P31/00 , A61P37/04 , C07K14/5412 , C07K14/5418 , C07K14/5434 , C07K14/5443 , C07K14/55 , C07K14/70514 , C07K14/70517 , C07K14/70521 , C12N2501/2302 , C12N2501/2307 , C12N2501/2315 , C12N2501/59 , C12N2502/1121 , C12N2502/1157
摘要： Safe, rapid and efficient methods for producing antigen-specific T cells recognizing human papilloma virus or HPV antigens.

8. 发明公开

EP3316896A1 DEVICE AND METHOD FOR OBTAINING IMMUNO-STIMULATORY ANTIGEN-PRESENTING CELLS 有权
标题翻译：用于获得免疫刺激性呈递细胞的装置和方法
公开(公告)号：EP3316896A1
公开(公告)日：2018-05-09
申请号：EP16734005.8
申请日：2016-07-04
申请人： Transimmune AG , Yale University
发明人： BAUER, Guenter , EDELSON, Richard , HENCO, Karsten , DUCKWORTH, Justin
IPC分类号： A61K35/15 , C12N5/0784
CPC分类号： C12N5/0639 , A61K35/15 , C12N5/0636 , C12N2502/1157
摘要： The present invention relates to methods for producing immuno-stimulatory antigen-presenting cells. The present invention further relates to the use of such cells for treating patients suffering from hyper-proliferative disease such as cancer.

9. 发明公开

EP2941256A4 CD11b- low MACROPHAGES AND CONDITIONED MEDIA THEREOF FOR TREATING CANCER AND/OR FIBROSIS 有权
标题翻译：巨噬细胞低CD11b的内容和条件培养基及其用于癌症和/或纤维化的治疗
公开(公告)号：EP2941256A4
公开(公告)日：2016-06-29
申请号：EP13867603
申请日：2013-12-30
申请人： UNIV CARMEL HAIFA ECONOMIC COR
发明人： BARKAN DALIT , GILON ODELYA , ARIEL AMIRAM , SCHIF-ZUCK SAGIE
IPC分类号： A61K35/12 , A61K35/15 , A61K45/06 , C12N5/077 , C12N5/0786
CPC分类号： A61K35/15 , A61K35/12 , A61K45/06 , C12N5/0645 , C12N5/0656 , C12N2500/70 , C12N2501/15 , C12N2501/58 , C12N2502/00 , C12N2502/1157 , C12N2506/11 , C12N2506/115 , C12N2506/1307
摘要： A conditioned medium of CD11blow macrophages and methods for preparing it are provided. Pharmaceutical compositions comprising the CD11blow macrophages conditioned medium or a culture of CD11blow macrophages and their use in the treatment of cancer or fibrosis are also provided.
摘要翻译：提供CD11blow巨噬细胞和其制备方法的条件培养基。因此，提供包含的巨噬细胞CD11blow条件培养基或巨噬细胞CD11blow的培养物及其在癌症或纤维化治疗中使用的药物组合物。

10. 发明公开

EP2565204A1 Novel immunogenic epitopes for immunotherapy 失效转让
标题翻译： Neuartige immunogenetische Epitope zur Immuntherapie
公开(公告)号：EP2565204A1
公开(公告)日：2013-03-06
申请号：EP12191631.6
申请日：2008-07-25
申请人： Immatics Biotechnologies GmbH
发明人： Singh, Harpreet , Schoor, Oliver , Trautwein, Claudia , Hilf, Norbert , Weinschenk, Toni , Walter, Steffen , Lewandrowski, Peter
IPC分类号： C07K14/47 , A61K39/00 , C07K14/495
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
摘要： The present invention relates to amino acid sequences of peptides derived from tumour associated antigens that are able to bind to MHC complexes of either class, and elicit an immune response, as well as to uses of said peptides for the treatment of diseases.
摘要翻译：本发明涉及能够结合任一类MHC复合物并引发免疫应答的衍生自肿瘤相关抗原的肽的氨基酸序列，以及所述肽用于治疗疾病的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式